asco 2022: trastuzumab deruxtecan vs. treatment of physician's choice in her2-low unresectable a...
Published 2 years ago • 6.5K plays • Length 7:39Download video MP4
Download video MP3
Similar videos
-
2:06
antibody-drug conjugates for her2-low disease: 2023 ku breast cancer year in review
-
2:12
trastuzumab deruxtecan in her2-low advanced breast cancer | nejm
-
1:33
questions remaining in the field of her2-low breast cancer
-
0:56
destiny-breast04: t-dxd for patients with her2-low mbc
-
24:38
stage 4 matastatic her 2 positive breast cancer third line enhertu and fourth line of treatment
-
5:05
anti-her2 mechanisms of approved her2 inhibitors
-
5:16
treatment options for her2-low breast cancer: all you need to know
-
4:03
trastuzumab deruxtecan significantly improves pfs in breast cancer patients previously treated w...
-
1:29
tuxedo-1: trastuzumab deruxtecan for the treatment of her2-positive breast cancer brain metastases
-
0:36
tucatinib & trastuzumab /- chemo or pembrolizumab in unresectable or metastatic her2 gi cancers
-
0:59
the significance of her2 expression for the activity of trastuzumab deruxtecan
-
0:31
remaining questions regarding her2-low breast cancer
-
0:44
patricia: phase ii study of palbociclib, trastuzumab, and endocrine therapy in her2 advanced bc
-
1:02
key takeaways from asco 2022
-
4:01
trastuzumab deruxtecan: a promising agent for treating her2-low breast cancer?
-
2:43
study of ds-8201a in her2-low, unresectable and/or metastatic breast cancer
-
1:39
pfs data support approval of fam-trastuzumab deruxtecan-nxki for her2 breast cancer
-
1:10
the evolution of her2-low-positive breast cancer as a clinical subtype
-
7:13
overview of the management of her2-low breast cancer patients
-
3:15
dr curigliano on the efficacy of t-dxd in her2-low and her2-ultralow breast cancer